(myalgia). In December 2021, the United States Food and Drug Administration (FDA) granted nirmatrelvir/ritonavir emergency use authorization (EUA) to treat
on 3 April 2022. Retrieved 13 May 2022. "Notice: Nirmatrelvir (COVID-19) added to PrescriptionDrug List (PDL)". Health Canada. 17 January 2022. Archived
such as migraine headache. Nirmatrelvir/ritonavir (Paxlovid) — granted emergency use authorization (EUA) by the US Food and Drug Administration (FDA) for
COVID-19 drug development is the research process to develop preventative therapeutic prescriptiondrugs that would alleviate the severity of coronavirus
fda.gov. FDA. Retrieved October 22, 2023. "Notice: Nirmatrelvir (COVID-19) added to PrescriptionDrug List (PDL)". Health Canada. January 17, 2022. Archived